CompletedNCT05903794
A Study of EXG102-031 in Patients With wAMD (Everest)
PHASE1 · 12 planned enrolment
- Countries listed
- 1
- Registry update
- April 8, 2026
immortal.lifeTrial registrations containing the exact intervention label EXG102-031.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE1 · 12 planned enrolment
PHASE1 · PHASE2 · 42 planned enrolment